Skip to main content

Drug Interactions between motixafortide and nebivolol / valsartan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nebivolol motixafortide

Applies to: nebivolol / valsartan and motixafortide

GENERALLY AVOID: Concomitant use of beta blockers may increase the risk or severity of hypotension and other serious reactions (e.g., angioedema, bronchospasm, bradycardia) in patients who experience hypersensitivity to motixafortide. The mechanism has not been clearly delineated, but it has been proposed that beta blockade may lead to an increase in intracellular synthesis and release of histamine and other anaphylactic mediators by disturbing the homeostatic balance between alpha- and beta-adrenergic and cholinergic neurohumoral mechanisms. Additionally, beta blockade may enhance the responsiveness of the pulmonary, cardiovascular, skin, and other systems to anaphylactic mediators. In clinical studies, anaphylactic shock and hypersensitivity reactions occurred in 0.7% and 7.6% of motixafortide-treated patients, respectively.

MANAGEMENT: Because anaphylaxis in patients treated with beta blockers may be more severe and protracted, the prescribing information for motixafortide recommends that alternative, non-chronotropic agents be used in place of beta blockers when possible. If coadministration cannot be avoided and anaphylaxis occurs, clinicians should be aware of potential resistance to conventional treatments such as epinephrine due to beta-adrenergic blockade. Aggressive treatment and prolonged supportive therapy may be required in refractory cases. The same precautions should be observed in patients treated with beta blocker ophthalmic solutions, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. All patients should be premedicated with a H1-antihistamine (e.g., diphenhydramine), a H2 antagonist (e.g., famotidine), and a leukotriene inhibitor (e.g., montelukast) 30 to 60 minutes prior to motixafortide administration to reduce the risk of anaphylactic shock and hypersensitivity reactions. Patients should be monitored for signs and symptoms of hypersensitivity for one hour following administration and managed accordingly.

References (2)
  1. (2023) "Product Information. Aphexda (motixafortide)." BioLineRx USA Inc
  2. Toogood JH (2023) Beta-blocker therapy and the risk of anaphylaxis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1491970/pdf/cmaj00141-0019.pdf

Drug and food interactions

Moderate

valsartan food

Applies to: nebivolol / valsartan

GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.

MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.

References (2)
  1. (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
  2. (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.